Cargando…
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and resistance to anticancer therapies highlighting the potential of Mcl-1 inhibitors as anticancer drugs. Here, we descri...
Autores principales: | Tron, Adriana E., Belmonte, Matthew A., Adam, Ammar, Aquila, Brian M., Boise, Lawrence H., Chiarparin, Elisabetta, Cidado, Justin, Embrey, Kevin J., Gangl, Eric, Gibbons, Francis D., Gregory, Gareth P., Hargreaves, David, Hendricks, J. Adam, Johannes, Jeffrey W., Johnstone, Ricky W., Kazmirski, Steven L., Kettle, Jason G., Lamb, Michelle L., Matulis, Shannon M., Nooka, Ajay K., Packer, Martin J., Peng, Bo, Rawlins, Philip B., Robbins, Daniel W., Schuller, Alwin G., Su, Nancy, Yang, Wenzhan, Ye, Qing, Zheng, Xiaolan, Secrist, J. Paul, Clark, Edwin A., Wilson, David M., Fawell, Stephen E., Hird, Alexander W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297231/ https://www.ncbi.nlm.nih.gov/pubmed/30559424 http://dx.doi.org/10.1038/s41467-018-07551-w |
Ejemplares similares
-
Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991
por: Goliaei, Ardeshir, et al.
Publicado: (2020) -
Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1
por: Hargreaves, David, et al.
Publicado: (2023) -
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
por: Bajpai, R, et al.
Publicado: (2015) -
P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY
por: Desai, Pinkal, et al.
Publicado: (2023) -
Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)